Hematologic diseases

Epidemiology of hematologic diseases concerns the risk and prognosis of both benign and malignant hematologic diseases. Hematologic diseases comprise a heterogeneous group of benign and malignant diseases originating from the cells of the bone marrow and the lymphatic system, which contributes substantially to global mortality and morbidity.

At DCE, patient groups with immune thrombocytopenia (ITP), myelodysplastic syndromes, acute myeloid leukemia, and lymphoma are of special interest.

Our ITP research focuses on the risk of thromboembolic events, the risk of bleeding, and mortality in patients with ITP. Currently, we are working on identifying prognostic factors and describing treatment trajectories for Danish ITP patients.

Within malignant hematologic diseases research, we focus on the role of patient-related factors, such as comorbidity and socioeconomic status, and clinical factors, such as the presence of anemia, in relation to treatment and overall survival. We also investigate how the presence of asthma and autoimmune diseases affects the risk of hematologic malignancies.

 

Selected DCE publications


Contact

Henrik Toft Sørensen

Clinical professor and chair, MD, PhD, DMSc
M
P +4587168215